Brachyury (** Currently investigational agents include GI-6301 (therapeutic vaccine) and other experimental immunotherapies in clinical trials. No FDA-approved brachyury-targeted therapies are currently available. **)

Description

Brachyury is a protein found on some cancer cells, including colorectal cancer. It is being investigated as a potential target for new cancer treatments. Currently, there are no FDA-approved drugs specifically targeting brachyury for colorectal cancer. However, research is ongoing to develop therapies that might target this protein or use it as a marker to identify patients who might benefit from certain treatments. Clinical trials are exploring different approaches, including vaccines designed to trigger an immune response against brachyury, often in combination with other immunotherapies or targeted agents.

Mechanism of Action

Brachyury is a protein involved in the development of certain tissues. In cancer, it can play a role in tumor growth and spread. Researchers are exploring ways to target this protein to disrupt cancer cell function or to stimulate the immune system to recognize and attack cancer cells expressing brachyury. The specific mechanisms being investigated in clinical trials often involve stimulating the body's own immune system (like with vaccines) to target cells displaying brachyury.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials